Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism

Open access

Abstract

Antagonism or agonism of the glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) prevents weight gain and leads to dramatic weight loss in combination with glucagon-like peptide-1 receptor agonists in preclinical models. Based on the genetic evidence supporting GIPR antagonism, we previously developed a mouse anti-murine GIPR antibody (muGIPR-Ab) that protected diet-induced obese (DIO) mice against body weight gain and improved multiple metabolic parameters. This work reconciles the similar preclinical body weight effects of GIPR antagonists and agonists in vivo, and here we show that chronic GIPR agonism desensitizes GIPR activity in primary adipocytes, both differentiated in vitro and adipose tissue in vivo, and functions like a GIPR antagonist. Additionally, GIPR activity in adipocytes is partially responsible for muGIPR-Ab to prevent weight gain in DIO mice, demonstrating a role of adipocyte GIPR in the regulation of adiposity in vivo.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-020-18751-8

Cites

Statistics

Figures

Fig. 1 Generation of a long-acting GIPR agonist (LA-Agonist) for chronic in vivo studies. a GIPR agonist activity of LA-Agonist and mouse GIP in cells overexpressing mouse GIPR determined by measuring cAMP. n = 2 wells/treatment. b, c Pharmacodynamic (PD) assay for LA-Agonist-stimulated insulin secretion. DIO mice were injected with saline or LA-Agonist, fasted for 4 h, injected with glucose and saline or glucose and DA-GIP as indicated. b Blood glucose and c plasma insulin were measured over time. n = 8 mice/group; two-way repeated measures ANOVA with Dunnett’s multiple comparisons test, **p = 0.0048 and ****p ≤ 0.0001 vs. vehicle/saline. Data are presented as mean values ± SEM. d, e LA-Agonist exposure from samples taken at 4-h post dose of LA-Agonist in the same PD assay presented in b, c were correlated to individual response for d glucose and e insulin, based on 0–60 min AUC calculated from b and c, respectively. n = 8 mice/treatment. Data are presented as mean values ± SEM. f Single-dose pharmacokinetic (PK) study of LA-Agonist was evaluated in CD-1 mice both by intravenous (IV) and intaperitoneal (IP) injections. Plasma was collected over time and used to measure intact LA-Agonist. n = 3 mice/timepoint. Data are presented as mean values ± SEM.
Fig. 1 Generation of a long-acting GIPR agonist (LA-Agonist) for chronic in vivo studies. a GIPR agonist activity of LA-Agonist and mouse GIP in cells overexpressing mouse GIPR determined by measuring cAMP. n = 2 wells/treatment. b, c Pharmacodynamic (PD) assay for LA-Agonist-stimulated insulin secretion. DIO mice were injected with saline or LA-Agonist, fasted for 4 h, injected with glucose and saline or glucose and DA-GIP as indicated. b Blood glucose and c plasma insulin were measured over time. n = 8 mice/group; two-way repeated measures ANOVA with Dunnett’s multiple comparisons test, **p = 0.0048 and ****p ≤ 0.0001 vs. vehicle/saline. Data are presented as mean values ± SEM. d, e LA-Agonist exposure from samples taken at 4-h post dose of LA-Agonist in the same PD assay presented in b, c were correlated to individual response for d glucose and e insulin, based on 0–60 min AUC calculated from b and c, respectively. n = 8 mice/treatment. Data are presented as mean values ± SEM. f Single-dose pharmacokinetic (PK) study of LA-Agonist was evaluated in CD-1 mice both by intravenous (IV) and intaperitoneal (IP) injections. Plasma was collected over time and used to measure intact LA-Agonist. n = 3 mice/timepoint. Data are presented as mean values ± SEM.CC BY · PubMed Central
Fig. 2 LA-Agonist has the same effect on body weight as muGIPR-Ab. a–k DIO mice dosed with vehicle, liraglutide, LA-Agonist, muGIPR-Ab, LA-Agonist + liraglutide, or muGIPR-Ab + liraglutide for 21 days. a Body weight change from day 1. On day 21, Vehicle vs. Liraglutide ****p ≤ 0.0001, Vehicle vs. LA-Agonist p = 0.077, Vehicle vs. muGIPR-Ab **p = 0.0082, Vehicle vs. Liraglutide + LA-Agonist ****p ≤ 0.0001, and Vehicle vs. Liraglutide + muGIPR-Ab ****p ≤ 0.0001. b 3-day average food intake measured over time. On days 1–3, **p = 0.0089 and ****p ≤ 0.0001; on days 7–9, ***p = 0.0020 and ****p ≤ 0.0001; and on days 13–15, **p = 0.0031 and ****p ≤ 0.0001. c Total fat mass measured by MRI on day 18. **p = 0.0032 and ****p ≤ 0.0001. Tissue weights collected at necropsy d scWAT, e eWAT, and f liver weights. d **p = 0.0044 and *p = 0.016, e *p = 0.040 and ****p ≤ 0.0001; and f Vehicle vs. Liraglutide *p = 0.017, Vehicle vs. LA-Agonist + Liraglutide *p = 0.021, and **p = 0.0059. Four-hour fasted plasma adipokines (g) leptin, (h) resistin, and (i) adiponectin collected on day 21. g *p = 0.018, **p = 0.0071, ***p = 0.0001, and ****p ≤ 0.0001; h ***p = 0.0001 and ****p ≤ 0.0001; and i *p = 0.027. j Plasma insulin and k blood glucose concentrations were measured before and after IP injections of DA-GIP and glucose. j At 15 min, Vehicle vs. Liraglutide *p = 0.026, Vehicle vs. muGIPR-Ab *p = 0.024, Vehicle vs. LA-Agonist + Liraglutide **p = 0.0022, Vehicle vs. muGIPR-Ab + Liraglutide **p = 0.0064, and LA-Agonist vs. muGIPR-Ab **p = 0.0043. k At 80 min, Vehicle vs. LA-Agonist ***p = 0.0009, Vehicle vs. LA-Agonist + Liraglutide ***p = 0.0001, and Vehicle vs. muGIPR-Ab + Liraglutide ***p = 0.0004. a–k n = 8 mice/group; a, j, k two-way repeated measures ANOVA with Tukey’s multiple comparisons test; b two-way ANOVA with Tukey’s multiple comparisons test; c–i one-way ANOVA with Sidak’s multiple comparisons test. Data are presented as mean values ± SEM.
Fig. 2 LA-Agonist has the same effect on body weight as muGIPR-Ab. a–k DIO mice dosed with vehicle, liraglutide, LA-Agonist, muGIPR-Ab, LA-Agonist + liraglutide, or muGIPR-Ab + liraglutide for 21 days. a Body weight change from day 1. On day 21, Vehicle vs. Liraglutide ****p ≤ 0.0001, Vehicle vs. LA-Agonist p = 0.077, Vehicle vs. muGIPR-Ab **p = 0.0082, Vehicle vs. Liraglutide + LA-Agonist ****p ≤ 0.0001, and Vehicle vs. Liraglutide + muGIPR-Ab ****p ≤ 0.0001. b 3-day average food intake measured over time. On days 1–3, **p = 0.0089 and ****p ≤ 0.0001; on days 7–9, ***p = 0.0020 and ****p ≤ 0.0001; and on days 13–15, **p = 0.0031 and ****p ≤ 0.0001. c Total fat mass measured by MRI on day 18. **p = 0.0032 and ****p ≤ 0.0001. Tissue weights collected at necropsy d scWAT, e eWAT, and f liver weights. d **p = 0.0044 and *p = 0.016, e *p = 0.040 and ****p ≤ 0.0001; and f Vehicle vs. Liraglutide *p = 0.017, Vehicle vs. LA-Agonist + Liraglutide *p = 0.021, and **p = 0.0059. Four-hour fasted plasma adipokines (g) leptin, (h) resistin, and (i) adiponectin collected on day 21. g *p = 0.018, **p = 0.0071, ***p = 0.0001, and ****p ≤ 0.0001; h ***p = 0.0001 and ****p ≤ 0.0001; and i *p = 0.027. j Plasma insulin and k blood glucose concentrations were measured before and after IP injections of DA-GIP and glucose. j At 15 min, Vehicle vs. Liraglutide *p = 0.026, Vehicle vs. muGIPR-Ab *p = 0.024, Vehicle vs. LA-Agonist + Liraglutide **p = 0.0022, Vehicle vs. muGIPR-Ab + Liraglutide **p = 0.0064, and LA-Agonist vs. muGIPR-Ab **p = 0.0043. k At 80 min, Vehicle vs. LA-Agonist ***p = 0.0009, Vehicle vs. LA-Agonist + Liraglutide ***p = 0.0001, and Vehicle vs. muGIPR-Ab + Liraglutide ***p = 0.0004. a–k n = 8 mice/group; a, j, k two-way repeated measures ANOVA with Tukey’s multiple comparisons test; b two-way ANOVA with Tukey’s multiple comparisons test; c–i one-way ANOVA with Sidak’s multiple comparisons test. Data are presented as mean values ± SEM.CC BY · PubMed Central
Fig. 3 Chronic LA-Agonist treatment has similar plasma metabolomics as muGIPR-Ab treatment, associated with agonist-induced receptor desensitization. a–e Global metabolomics analysis of plasma samples for vehicle, LA-Agonist, and muGIPR-Ab treated mice (presented in Fig. 2a–k). Significantly different number of metabolites between a vehicle vs. muGIPR-Ab, b vehicle vs. LA-Agonist, and c muGIPR-Ab vs. LA-Agonist. n = 8 mice/group; Welch’s two-sample t-test p ≤ 0.05 and Storey method for correcting multiple comparisons q-value ≤ 0.2. d Principal component analysis (PCA) of the plasma metabolites from global metabolomics analysis. e Significantly enriched pathways between vehicle vs. muGIPR-Ab and vehicle vs. LA-Agonist treatments. f–h Plasma metabolites f cAMP, g corticosterone, and h glycerol. Data are scaled such that the median value measured across all samples was set to 1.0 ± SEM, n = 8 mice/group; Welch’s two-sample t-test, f Vehicle vs. LA-Agonist *p = 0.0101 and Vehicle vs. muGIPR-Ab *p = 0.0121; g **p = 0.0023, and ***p = 0.000865; h *p = 0.029. i, j DIO mice were injected with saline or DA-GIP, and blood was collected 30 mins post-dose to measure plasma metabolites i corticosterone and j glycerol. n = 8 mice/group; one-way ANOVA with Sidak’s multiple comparisons test, i *p = 0.017 and **p = 0.0047, j *p = 0.043. Data are presented as mean values ± SEM. k, l DIO mice were pre-treated with vehicle or muGIPR-Ab 24-h before injection with saline or DA-GIP and plasma metabolites k corticosterone and l glycerol were measured over time. n = 10 mice/group; two-way repeated measures ANOVA with Sidak’s multiple comparisons test, k *p = 0.043, l *p = 0.029. Data are presented as mean values ± SEM. m, n cAMP concentration in mouse primary adipocytes (m) treated with GIP or (n) pre-treated with muGIPR-Ab overnight then treated with 10 nM mouse GIP. Data represents means ± SEM of three mice with three wells/treatment/mouse. o, p GIP-stimulated lipolysis in primary differentiated mouse pre-adipocytes o treated with mouse GIP compared to basal or p after pre-treatment with muGIPR-Ab overnight then treated with 10 nM mouse GIP. Data represent means ± SEM of 3–6 mice with three wells/treatment/mouse.
Fig. 3 Chronic LA-Agonist treatment has similar plasma metabolomics as muGIPR-Ab treatment, associated with agonist-induced receptor desensitization. a–e Global metabolomics analysis of plasma samples for vehicle, LA-Agonist, and muGIPR-Ab treated mice (presented in Fig. 2a–k). Significantly different number of metabolites between a vehicle vs. muGIPR-Ab, b vehicle vs. LA-Agonist, and c muGIPR-Ab vs. LA-Agonist. n = 8 mice/group; Welch’s two-sample t-test p ≤ 0.05 and Storey method for correcting multiple comparisons q-value ≤ 0.2. d Principal component analysis (PCA) of the plasma metabolites from global metabolomics analysis. e Significantly enriched pathways between vehicle vs. muGIPR-Ab and vehicle vs. LA-Agonist treatments. f–h Plasma metabolites f cAMP, g corticosterone, and h glycerol. Data are scaled such that the median value measured across all samples was set to 1.0 ± SEM, n = 8 mice/group; Welch’s two-sample t-test, f Vehicle vs. LA-Agonist *p = 0.0101 and Vehicle vs. muGIPR-Ab *p = 0.0121; g **p = 0.0023, and ***p = 0.000865; h *p = 0.029. i, j DIO mice were injected with saline or DA-GIP, and blood was collected 30 mins post-dose to measure plasma metabolites i corticosterone and j glycerol. n = 8 mice/group; one-way ANOVA with Sidak’s multiple comparisons test, i *p = 0.017 and **p = 0.0047, j *p = 0.043. Data are presented as mean values ± SEM. k, l DIO mice were pre-treated with vehicle or muGIPR-Ab 24-h before injection with saline or DA-GIP and plasma metabolites k corticosterone and l glycerol were measured over time. n = 10 mice/group; two-way repeated measures ANOVA with Sidak’s multiple comparisons test, k *p = 0.043, l *p = 0.029. Data are presented as mean values ± SEM. m, n cAMP concentration in mouse primary adipocytes (m) treated with GIP or (n) pre-treated with muGIPR-Ab overnight then treated with 10 nM mouse GIP. Data represents means ± SEM of three mice with three wells/treatment/mouse. o, p GIP-stimulated lipolysis in primary differentiated mouse pre-adipocytes o treated with mouse GIP compared to basal or p after pre-treatment with muGIPR-Ab overnight then treated with 10 nM mouse GIP. Data represent means ± SEM of 3–6 mice with three wells/treatment/mouse.CC BY · PubMed Central
Fig. 4 GIP stimulates fatty acid uptake in primary adipocytes in vitro and in adipose tissue in vivo and is inhibited by muGIPR-Ab. a FA uptake rate in primary differentiated mouse pre-adipocytes treated with GIP for 30 mins then FA uptake rate measured. Data represent mean ± SEM of adipocytes from four mice, three wells/treatment/mouse; Student’s paired t test, *p = 0.023. b FA uptake rate in primary differentiated mouse pre-adipocytes pre-treated with muGIPR-Ab or vehicle overnight then treatment with 10 nM GIP for 30 mins and FA uptake rate measured. Data represent mean ± SEM of adipocytes from three mice, three wells/treatment/mouse. c–i DIO mice were pre-treated with vehicle or muGIPR-Ab (25 mg/kg) for 24 h then injected with saline or DA-GIP and simultaneously oral gavaged with 14C-oleic acid in olive oil to assess FA uptake. c Plasma insulin measured over time, *p = 0.038 and ****p ≤ 0.0001. Radioactivity uptake into metabolically relevant tissues was measured at necropsy 180 min post-dose in d scWAT, e eWAT, f liver, g skeletal muscle, h brown adipose tissue, and i heart. d Vehicle vs. DA-GIP *p = 0.023 and Vehicle vs. muGIPR-Ab/DA-GIP *p = 0.043, f *p = 0.050. n = 8 mice/group; c two-way repeated measures ANOVA with Tukey’s test for multiple comparisons (c) or (d–i) one-way ANOVA with Tukey’s test for multiple comparisons test, *p ≤ 0.05 and ****p ≤ 0.0001. Data are presented as mean values ± SEM.
Fig. 4 GIP stimulates fatty acid uptake in primary adipocytes in vitro and in adipose tissue in vivo and is inhibited by muGIPR-Ab. a FA uptake rate in primary differentiated mouse pre-adipocytes treated with GIP for 30 mins then FA uptake rate measured. Data represent mean ± SEM of adipocytes from four mice, three wells/treatment/mouse; Student’s paired t test, *p = 0.023. b FA uptake rate in primary differentiated mouse pre-adipocytes pre-treated with muGIPR-Ab or vehicle overnight then treatment with 10 nM GIP for 30 mins and FA uptake rate measured. Data represent mean ± SEM of adipocytes from three mice, three wells/treatment/mouse. c–i DIO mice were pre-treated with vehicle or muGIPR-Ab (25 mg/kg) for 24 h then injected with saline or DA-GIP and simultaneously oral gavaged with 14C-oleic acid in olive oil to assess FA uptake. c Plasma insulin measured over time, *p = 0.038 and ****p ≤ 0.0001. Radioactivity uptake into metabolically relevant tissues was measured at necropsy 180 min post-dose in d scWAT, e eWAT, f liver, g skeletal muscle, h brown adipose tissue, and i heart. d Vehicle vs. DA-GIP *p = 0.023 and Vehicle vs. muGIPR-Ab/DA-GIP *p = 0.043, f *p = 0.050. n = 8 mice/group; c two-way repeated measures ANOVA with Tukey’s test for multiple comparisons (c) or (d–i) one-way ANOVA with Tukey’s test for multiple comparisons test, *p ≤ 0.05 and ****p ≤ 0.0001. Data are presented as mean values ± SEM.CC BY · PubMed Central
Fig. 5 Mice with adipocyte Gipr knockout have reduced diet-induced fat mass accumulation. a Gipr RNA expression in primary isolated adipocytes from scWAT from male Giprfl/fl and GiprAdipo−/− littermates fed HFD for 10 weeks; n = 4 mice/group, Student’s paired t test, *p = 0.039. b Gipr and c Adipoq RNA expression in primary mouse pre-adipocytes differentiated in vitro from male Giprfl/fl and GiprAdipo−/− littermates fed HFD for 18 weeks; n = 5 mice/group, Student’s paired t test, **p = 0.0078. d Gipr RNA expression in islets, brown adipose tissue (BAT), and adrenal glands relative to Giprfl/fl islets from male Giprfl/fl and GiprAdipo−/− littermates fed HFD for 18 weeks; n = 8 Giprfl/fl and n = 5 GiprAdipo−/−, Student’s unpaired t-test. e GIP-stimulated GIPR activity in primary mouse pre-adipocytes differentiated in vitro from male Giprfl/fl and GiprAdipo−/− littermates fed HFD for 18 weeks; n = 5 mice, three wells/treatment/mouse, Two-way repeated measures ANOVA with Tukey’s HSD for multiple comparisons, Giprfl/fl/Basal vs. Giprfl/fl/100 nM ***p = 0.0003 and Giprfl/fl/100 nM vs. GiprAdipo−/−/100 nM ***p = 0.0009. f FA uptake rate in primary differentiated mouse pre-adipocytes differentiated in vitro from male Giprfl/fl and GiprAdipo−/− littermates fed HFD for 18 weeks. n = 5 mice, three wells/treatment/mouse, two-way repeated measures ANOVA with Tukey’s HSD for multiple comparisons, *p = 0.022, **p = 0.0050. g–j Male Giprfl/fl and GiprAdipo−/− littermates fed HFD for 12 weeks and g body weight measured over time, h food intake determined at week 12 HFD feeding, and i lean mass and j fat mass measured by MRI at week 12 HFD feeding. n = 16 Giprfl/fl mice and n = 15 GiprAdipo−/− mice, ****p ≤ 0.0001, g two-way repeated measures ANOVA with Sidak’s test for multiple comparisons, h–j Student’s unpaired t-test. k, l GIP-stimulated fatty acid uptake into scWAT of male Giprfl/fl and GiprAdipo−/− littermates fed HFD for 12 weeks. k ScWAT weight was measured at necropsy 180 mins post-dose and l radioactivity uptake into scWAT was determined. n = 7 mice/group, Student’s unpaired t-test, ****p ≤ 0.0001 and *p = 0.050. a–l Data are presented as mean values ± SEM.
Fig. 5 Mice with adipocyte Gipr knockout have reduced diet-induced fat mass accumulation. a Gipr RNA expression in primary isolated adipocytes from scWAT from male Giprfl/fl and GiprAdipo−/− littermates fed HFD for 10 weeks; n = 4 mice/group, Student’s paired t test, *p = 0.039. b Gipr and c Adipoq RNA expression in primary mouse pre-adipocytes differentiated in vitro from male Giprfl/fl and GiprAdipo−/− littermates fed HFD for 18 weeks; n = 5 mice/group, Student’s paired t test, **p = 0.0078. d Gipr RNA expression in islets, brown adipose tissue (BAT), and adrenal glands relative to Giprfl/fl islets from male Giprfl/fl and GiprAdipo−/− littermates fed HFD for 18 weeks; n = 8 Giprfl/fl and n = 5 GiprAdipo−/−, Student’s unpaired t-test. e GIP-stimulated GIPR activity in primary mouse pre-adipocytes differentiated in vitro from male Giprfl/fl and GiprAdipo−/− littermates fed HFD for 18 weeks; n = 5 mice, three wells/treatment/mouse, Two-way repeated measures ANOVA with Tukey’s HSD for multiple comparisons, Giprfl/fl/Basal vs. Giprfl/fl/100 nM ***p = 0.0003 and Giprfl/fl/100 nM vs. GiprAdipo−/−/100 nM ***p = 0.0009. f FA uptake rate in primary differentiated mouse pre-adipocytes differentiated in vitro from male Giprfl/fl and GiprAdipo−/− littermates fed HFD for 18 weeks. n = 5 mice, three wells/treatment/mouse, two-way repeated measures ANOVA with Tukey’s HSD for multiple comparisons, *p = 0.022, **p = 0.0050. g–j Male Giprfl/fl and GiprAdipo−/− littermates fed HFD for 12 weeks and g body weight measured over time, h food intake determined at week 12 HFD feeding, and i lean mass and j fat mass measured by MRI at week 12 HFD feeding. n = 16 Giprfl/fl mice and n = 15 GiprAdipo−/− mice, ****p ≤ 0.0001, g two-way repeated measures ANOVA with Sidak’s test for multiple comparisons, h–j Student’s unpaired t-test. k, l GIP-stimulated fatty acid uptake into scWAT of male Giprfl/fl and GiprAdipo−/− littermates fed HFD for 12 weeks. k ScWAT weight was measured at necropsy 180 mins post-dose and l radioactivity uptake into scWAT was determined. n = 7 mice/group, Student’s unpaired t-test, ****p ≤ 0.0001 and *p = 0.050. a–l Data are presented as mean values ± SEM.CC BY · PubMed Central
Fig. 6 GIPR activity in adipocytes partially contributes to the effect of muGIPR-Ab to prevent weight gain in DIO mice. Male a Giprfl/fl and b GiprAdipo−/− littermates fed HFD for 12 weeks (represented in Fig. 5g–j) were treated with vehicle or muGIPR-Ab (25 mg/kg every 6 days) for 48 days and body weight change measured over time. n = 8 mice/group Giprfl/fl/Vehicle, Giprfl/fl/muGIPR-Ab, and GiprAdipo−/−/Vehicle, and n = 7 mice GiprAdipo−/−/muGIPR-Ab; two-way repeated measures ANOVA with Sidak’s test for multiple comparisons; a day 10 *p = 0.028, day 13 *p = 0.035, day 15 **p = 0.0082, and days 19–48 ****p ≤ 0.0001. Data are presented as mean values ± SEM. Female (c) Giprfl/fl and (d) GiprAdipo−/− littermates fed HFD for 8 weeks were treated with vehicle or muGIPR-Ab (25 mg/kg every 6 days) for 67 days and body weight change measured over time. n = 5 mice/group Giprfl/fl/Vehicle, Giprfl/fl/muGIPR-Ab, and GiprAdipo−/−/muGIPR-Ab, and n = 4 mice GiprAdipo−/−/Vehicle; two-way repeated measures ANOVA with Sidak’s test for multiple comparisons; c day 43 *p = 0.027, day 46 *p = 0.018, days 49-48 **p ≤ 0.0050, days 61–67 ***p ≤ 0.008. Data are presented as mean values ± SEM. e Liver weight from male Giprfl/fl and GiprAdipo−/− treated with vehicle or muGIPR-Ab for 48 days were collected at necropsy, one-way ANOVA with Sidak’s test for multiple comparisons, *p = 0.024. Hepatic f fat oxidation and g lipogenesis genes were measured by Quantigene Plex. n = 8 mice/group Giprfl/fl/Vehicle, Giprfl/fl/muGIPR-Ab, and GiprAdipo−/−/Vehicle, and n = 7 mice GiprAdipo−/−/muGIPR-Ab; two-way ANOVA with Sidak’s test for multiple comparisons; Ppara *p = 0.033, Acaa2 *p = 0.032, Acadm *p = 0.025, and Cpt2 *p = 0.042. Data are presented as mean values ± SEM.
Fig. 6 GIPR activity in adipocytes partially contributes to the effect of muGIPR-Ab to prevent weight gain in DIO mice. Male a Giprfl/fl and b GiprAdipo−/− littermates fed HFD for 12 weeks (represented in Fig. 5g–j) were treated with vehicle or muGIPR-Ab (25 mg/kg every 6 days) for 48 days and body weight change measured over time. n = 8 mice/group Giprfl/fl/Vehicle, Giprfl/fl/muGIPR-Ab, and GiprAdipo−/−/Vehicle, and n = 7 mice GiprAdipo−/−/muGIPR-Ab; two-way repeated measures ANOVA with Sidak’s test for multiple comparisons; a day 10 *p = 0.028, day 13 *p = 0.035, day 15 **p = 0.0082, and days 19–48 ****p ≤ 0.0001. Data are presented as mean values ± SEM. Female (c) Giprfl/fl and (d) GiprAdipo−/− littermates fed HFD for 8 weeks were treated with vehicle or muGIPR-Ab (25 mg/kg every 6 days) for 67 days and body weight change measured over time. n = 5 mice/group Giprfl/fl/Vehicle, Giprfl/fl/muGIPR-Ab, and GiprAdipo−/−/muGIPR-Ab, and n = 4 mice GiprAdipo−/−/Vehicle; two-way repeated measures ANOVA with Sidak’s test for multiple comparisons; c day 43 *p = 0.027, day 46 *p = 0.018, days 49-48 **p ≤ 0.0050, days 61–67 ***p ≤ 0.008. Data are presented as mean values ± SEM. e Liver weight from male Giprfl/fl and GiprAdipo−/− treated with vehicle or muGIPR-Ab for 48 days were collected at necropsy, one-way ANOVA with Sidak’s test for multiple comparisons, *p = 0.024. Hepatic f fat oxidation and g lipogenesis genes were measured by Quantigene Plex. n = 8 mice/group Giprfl/fl/Vehicle, Giprfl/fl/muGIPR-Ab, and GiprAdipo−/−/Vehicle, and n = 7 mice GiprAdipo−/−/muGIPR-Ab; two-way ANOVA with Sidak’s test for multiple comparisons; Ppara *p = 0.033, Acaa2 *p = 0.032, Acadm *p = 0.025, and Cpt2 *p = 0.042. Data are presented as mean values ± SEM.CC BY · PubMed Central
Fig. 7 Chronic GIPR agonism desensitizes GIPR activity in primary adipocytes. a cAMP measurements in primary differentiated mouse pre-adipocytes pre-treated with or without DA-GIP (1 μM) for 24 h then treated with vehicle, mouse GIP, or isoproterenol (1 μM) for 30 min; *p = 0.010, ****p ≤ 0.0001. b cAMP measurements in primary differentiated mouse pre-adipocytes pre-treated with or without DA-GIP (1 μM) for 24 h, washed, then treated with 100 nM mouse GIP for 30 min; ***p = 0.0003, ****p ≤ 0.0001. c cAMP measurements in primary differentiated mouse pre-adipocytes pre-treated with or without DA-GIP (1 μM) for 1, 4, or 24 h, then treated with 100 nM mouse GIP for 30 min; ****p ≤ 0.0001, ***p = 0.0003, 0/No GIP vs. 4 h/No GIP *p = 0.021, and 0/No GIP vs. 24 h/No GIP *p = 0.027. d cAMP measurements in primary differentiated mouse pre-adipocytes pre-treated with or without DA-GIP for 24 h, then treated with 100 nM mouse GIP for 30 min. ****p ≤ 0.0001. e FA uptake in primary differentiated mouse pre-adipocytes pre-treated with or without DA-GIP for 24 h, then treated with vehicle, mouse GIP, or insulin for 30 min. *p = 0.015, No DA-GIP Basal vs. No DA-GIP/Insulin **p = 0.0044, DA-GIP/Basal vs. DA-GIP/Insulin **p = 0.0022. f cAMP measurements in primary human adipocytes differentiated in vitro pre-treated with or without DA-GIP for 24 h then treated with vehicle, human GIP, or isoproterenol for 30 min. *p = 0.011, ***p = 0.0009, 100 nM GIP/No DA-GIP vs. 100 nM GIP DA-GIP **p = 0.0065, and Basal/DA-GIP vs. Isoproterenol/DA-GIP **p = 0.0011. a–f Data represent means ± SEM of four mice with three wells/treatment/mouse (a–d), three mice with three wells/treatment/mouse (e), three human donors with three wells/treatment/person (f); two-way repeated measures ANOVA with Sidak’s multiple comparisons test. g Mouse Neuro-2a neuroblastoma cells and h rat INS1 832/13 islet cells pre-treated with mouse or rat GIP (1 μM), respectively, for 24 h then treated with mouse or rat GIP in a dose response for 15 min; n = 2 wells/treatment.
Fig. 7 Chronic GIPR agonism desensitizes GIPR activity in primary adipocytes. a cAMP measurements in primary differentiated mouse pre-adipocytes pre-treated with or without DA-GIP (1 μM) for 24 h then treated with vehicle, mouse GIP, or isoproterenol (1 μM) for 30 min; *p = 0.010, ****p ≤ 0.0001. b cAMP measurements in primary differentiated mouse pre-adipocytes pre-treated with or without DA-GIP (1 μM) for 24 h, washed, then treated with 100 nM mouse GIP for 30 min; ***p = 0.0003, ****p ≤ 0.0001. c cAMP measurements in primary differentiated mouse pre-adipocytes pre-treated with or without DA-GIP (1 μM) for 1, 4, or 24 h, then treated with 100 nM mouse GIP for 30 min; ****p ≤ 0.0001, ***p = 0.0003, 0/No GIP vs. 4 h/No GIP *p = 0.021, and 0/No GIP vs. 24 h/No GIP *p = 0.027. d cAMP measurements in primary differentiated mouse pre-adipocytes pre-treated with or without DA-GIP for 24 h, then treated with 100 nM mouse GIP for 30 min. ****p ≤ 0.0001. e FA uptake in primary differentiated mouse pre-adipocytes pre-treated with or without DA-GIP for 24 h, then treated with vehicle, mouse GIP, or insulin for 30 min. *p = 0.015, No DA-GIP Basal vs. No DA-GIP/Insulin **p = 0.0044, DA-GIP/Basal vs. DA-GIP/Insulin **p = 0.0022. f cAMP measurements in primary human adipocytes differentiated in vitro pre-treated with or without DA-GIP for 24 h then treated with vehicle, human GIP, or isoproterenol for 30 min. *p = 0.011, ***p = 0.0009, 100 nM GIP/No DA-GIP vs. 100 nM GIP DA-GIP **p = 0.0065, and Basal/DA-GIP vs. Isoproterenol/DA-GIP **p = 0.0011. a–f Data represent means ± SEM of four mice with three wells/treatment/mouse (a–d), three mice with three wells/treatment/mouse (e), three human donors with three wells/treatment/person (f); two-way repeated measures ANOVA with Sidak’s multiple comparisons test. g Mouse Neuro-2a neuroblastoma cells and h rat INS1 832/13 islet cells pre-treated with mouse or rat GIP (1 μM), respectively, for 24 h then treated with mouse or rat GIP in a dose response for 15 min; n = 2 wells/treatment.CC BY · PubMed Central
Fig. 8 Chronic GIPR agonism increases membrane GIPR internalization in vitro. a HEK293T cells overexpressing GIPR used to determine homologous whole cells 125I-GIP membrane binding. Cells treated with or without DA-GIP, washed, and binding using 125I-labeled human GIP was measure as CPM in a TopCount NXT gamma counter and plotted as % 125I-GIP bound. n = 2 wells/treatment. b, c Comparison of whole cell, membrane, and intracellular GIPR (red, Alexa Fluor 647) content in CHOK1 cells overexpressing GIPR pre-treated with or without DA-GIP for 24 h. b Quantitated GIPR fluorescence (RFU) and c representative image. n = 6 wells/treatment, two-way ANOVA with Sidak’s test for multiple comparisons, ****p ≤ 0.0001. Data are presented as mean values ± SEM. d, e Time course comparison of GIPR internalization upon stimulation with GIP in CHOK1 cells overexpressing GIPR (red, Alexa Fluor 647) pre-treated with or without DA-GIP for 24 h. d, Quantitated membrane GIPR fluorescence (RFU) with background fluorescence subtracted and e, representative images, n = 3 wells/treatment. Data are presented as mean values ± SEM.
Fig. 8 Chronic GIPR agonism increases membrane GIPR internalization in vitro. a HEK293T cells overexpressing GIPR used to determine homologous whole cells 125I-GIP membrane binding. Cells treated with or without DA-GIP, washed, and binding using 125I-labeled human GIP was measure as CPM in a TopCount NXT gamma counter and plotted as % 125I-GIP bound. n = 2 wells/treatment. b, c Comparison of whole cell, membrane, and intracellular GIPR (red, Alexa Fluor 647) content in CHOK1 cells overexpressing GIPR pre-treated with or without DA-GIP for 24 h. b Quantitated GIPR fluorescence (RFU) and c representative image. n = 6 wells/treatment, two-way ANOVA with Sidak’s test for multiple comparisons, ****p ≤ 0.0001. Data are presented as mean values ± SEM. d, e Time course comparison of GIPR internalization upon stimulation with GIP in CHOK1 cells overexpressing GIPR (red, Alexa Fluor 647) pre-treated with or without DA-GIP for 24 h. d, Quantitated membrane GIPR fluorescence (RFU) with background fluorescence subtracted and e, representative images, n = 3 wells/treatment. Data are presented as mean values ± SEM.CC BY · PubMed Central
Fig. 9 Chronic GIPR agonism desensitizes adipocyte GIPR activity in vivo mimicking GIPR antagonism. GIP-stimulated FA uptake in DIO mice treated with vehicle, LA-Agonist, or muGIPR-Ab for 6 days. On day 6, mice were injected with saline or DA-GIP and simultaneously oral gavaged with 14C-oleic acid in olive oil to assess FA uptake. a Cumulative food intake determined; *p = 0.036, **p = 0.0075. b Fasting blood glucose and c plasma insulin were measured on day 6; ****p ≤ 0.0001. Data represent means ± SEM of 16 mice for vehicle group (divided into two groups of 8 for the FA uptake assay) and eight mice/group for the LA-Agonist and muGIPR-Ab groups. d Body weight, e scWAT weight, f eWAT weight, and g liver weight were measured at necropsy on day 6. Radioactivity uptake into metabolically relevant tissues was determined at necropsy in h scWAT, i eWAT, j liver, and k skeletal muscle. h Vehicle/DA-GIP vs. Vehicle/Saline *p = 0.027, Vehicle/DA-GIP vs. muGIPR-Ab/DA-GIP *p = 0.014, Vehicle/DA-GIP vs. LA-Agonist/DA-GIP *p = 0.014; j *p = 0.041. n = 8 mice/group. a–k One-way ANOVA with Sidak’s test for multiple comparisons; *p ≤ 0.05, **p ≤ 0.01, and ****p ≤ 0.0001. Data are presented as mean values ± SEM.
Fig. 9 Chronic GIPR agonism desensitizes adipocyte GIPR activity in vivo mimicking GIPR antagonism. GIP-stimulated FA uptake in DIO mice treated with vehicle, LA-Agonist, or muGIPR-Ab for 6 days. On day 6, mice were injected with saline or DA-GIP and simultaneously oral gavaged with 14C-oleic acid in olive oil to assess FA uptake. a Cumulative food intake determined; *p = 0.036, **p = 0.0075. b Fasting blood glucose and c plasma insulin were measured on day 6; ****p ≤ 0.0001. Data represent means ± SEM of 16 mice for vehicle group (divided into two groups of 8 for the FA uptake assay) and eight mice/group for the LA-Agonist and muGIPR-Ab groups. d Body weight, e scWAT weight, f eWAT weight, and g liver weight were measured at necropsy on day 6. Radioactivity uptake into metabolically relevant tissues was determined at necropsy in h scWAT, i eWAT, j liver, and k skeletal muscle. h Vehicle/DA-GIP vs. Vehicle/Saline *p = 0.027, Vehicle/DA-GIP vs. muGIPR-Ab/DA-GIP *p = 0.014, Vehicle/DA-GIP vs. LA-Agonist/DA-GIP *p = 0.014; j *p = 0.041. n = 8 mice/group. a–k One-way ANOVA with Sidak’s test for multiple comparisons; *p ≤ 0.05, **p ≤ 0.01, and ****p ≤ 0.0001. Data are presented as mean values ± SEM.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 38 · Cited by 151

Research works printed but not linked: 1

  1. Noerregaard, P. et al. A novel GIP receptor agonist enhances the body weight lowering effect of liraglutide in diet-induced obese mice and has the potential for once-weekly administration in humans. Diabetologia 58, S838 (2015).

Metadata

Authors
Killion, E. A., Chen, M., Falsey, J. R., Sivits, G., Hager, T., Atangan, L., Helmering, J., Lee, J., Li, H., Wu, B., Cheng, Y., Véniant, M. M., & Lloyd, D. J.
Affiliations
Amgen (United States) (US)
Corresponding author
Lloyd, David J.
Venue
Nature Communications
Published
2020-10-05
Volume
11
Issue
1
Pages
4981-4981
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3090919864
Cited by
151
References
38
Citations by year
2026: 27 · 2025: 38 · 2024: 30 · 2023: 14 · 2022: 23 · 2021: 17 · 2020: 2
FWCI
7.18
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Amgen
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
Keywords
glucose-dependent insulinotropic polypeptide, GIP receptor, receptor desensitization, adipocytes, diet-induced obesity, weight gain, GLP-1 receptor, adipose tissue
MeSH terms
Cyclic AMP, Adipose Tissue, Animals, Antibodies, Body Weight, Cell Membrane, Cells, Cultured, Fatty Acids, Gastric Inhibitory Polypeptide, Humans, Mice, Inbred C57BL, Obesity, Receptors, Gastrointestinal Hormone, Adipocytes, Mice, Knockout, Anti-Obesity Agents, Mice, Diet, High-Fat

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism. https://app.cochat.ai/papers/10.1038/s41467-020-18751-8
The paper
Killion, E. A., Chen, M., Falsey, J. R., Sivits, G., Hager, T., Atangan, L., Helmering, J., Lee, J., Li, H., Wu, B., Cheng, Y., Véniant, M. M., & Lloyd, D. J. (2020). Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism. Nature Communications. https://doi.org/10.1038/s41467-020-18751-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.